Who are Gabapentin, Estrogen and placebo administration's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gabapentin-estrogen-and-placebo-administration.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Gabapentin, Estrogen and placebo administration — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gabapentin, Estrogen and placebo administration (Gabapentin, Estrogen and placebo administration) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy (gabapentinoid + hormone replacement therapy). Area: Gynecology / Menopause.

marketed Combination therapy (gabapentinoid + hormone replacement therapy) Voltage-gated calcium channel (alpha-2-delta subunit) for gabapentin; estrogen receptor for estrogen Gynecology / Menopause Small molecule Live · refreshed every 30 min

Target snapshot

Gabapentin, Estrogen and placebo administration (Gabapentin, Estrogen and placebo administration) — University of Rochester. This is a research combination of gabapentin (a gabapentinoid that modulates calcium channels) and estrogen (a hormone replacement therapy) tested together, likely to evaluate synergistic effects on vasomotor symptoms or neuropathic pain in menopausal women.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gabapentin, Estrogen and placebo administration TARGET	Gabapentin, Estrogen and placebo administration	University of Rochester	marketed	Combination therapy (gabapentinoid + hormone replacement therapy)	Voltage-gated calcium channel (alpha-2-delta subunit) for gabapentin; estrogen receptor for estrogen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy (gabapentinoid + hormone replacement therapy) class)

University of Rochester · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gabapentin, Estrogen and placebo administration — Competitive Intelligence Brief. https://druglandscape.com/ci/gabapentin-estrogen-and-placebo-administration. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab